Business Wire

PITCH

20.5.2021 15:12:07 CEST | Business Wire | Press release

Share
Pitch Raises $85 Million To Build The First Complete Platform for Presentations

Pitch , the collaborative presentation platform for modern teams, today announced that it has raised an $85 million Series B funding round led by Lakestar and Tiger Global, and joined by existing Pitch investors Index Ventures and Thrive Capital.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210520005667/en/

Six months after launching to the public, the Series B investment comes at a time of significant growth and momentum for Pitch. To date, tens of thousands of teams have opened 125,000 workspaces on Pitch, including top companies like Intercom, Superhuman and Notion.

“Our mission at Pitch is to enable every team’s best thinking,” said Christian Reber, Founder & CEO of Pitch. “It’s been six months since we launched to the world, and tens of thousands of teams have already discovered how easy it is to create, collaborate on and deliver beautiful presentations on Pitch. We’re thrilled to have two world-class partners in Tiger Global and Lakestar onboard as we pursue our vision to build the first complete platform for presentations.”

A new kind of platform

To accelerate its momentum in the year ahead, Pitch plans to use the new funding to develop its core technology and product, grow its global team, and extend its software platform across the entire presentation workflow.

  • A publishing and content ecosystem: Pitch is building a dedicated home for publishing and exchanging presentations and templates. In this new ecosystem, users will be able to discover content from top creators and brands, and publish their own work directly to public profile pages. In the upcoming weeks, Pitch will launch the first of these pages for a select group of creators, and will open up access to all users later this year.
  • Advanced presentation analytics: Pitch is building new integrated solutions for users to better distribute presentations and monitor performance. Rolling out in multiple stages this summer, these new features will enable secure sharing and advanced analytics within Pitch, and will give users detailed insights into the reach and readership of a presentation, engagement levels on specific slides, and more.
  • Narrative recording and playback: Pitch is building new ways to highlight, record, and play back presentations in any context. Designed for a more remote, asynchronous world of work, these tools will ensure presenters and recipients can engage across an expanded range of meeting formats and team workflows. These tools are currently in beta, and will be rolled out in stages to users in the coming months.

“The exciting vision that Christian and the team at Pitch have is beyond just being a superior alternative to legacy presentation software," said Stephen Nundy, Partner at Lakestar. "A reimagining of the entire workflow surrounding presentations is very much overdue, and when coupled with the ability to harness new data and media integrations, Pitch will lead the way in changing how stories are told. I’m very proud to be joining the board of a European company with its sights set on a truly global opportunity.”

“We are incredibly impressed by the quality of Pitch’s offering today and Christian’s vision for the future. Pitch will be a true productivity platform, and we are excited to become investors in this special company,” says John Curtius, Partner at Tiger Global.

Pitch offers both free and paid plans for teams of all sizes. With Pitch Pro, teams unlock access to unlimited storage, video uploads, version history, and advanced permissioning for $10 per member per month.

About Pitch

Pitch is the collaborative presentation software for modern teams. With a focus on real-time collaboration, smart workflows, and intuitive design features, Pitch makes it fast and delightful for teams to create and deliver beautiful presentations, and easy for anyone to find inspiration from templates crafted by experts. Tens of thousands of teams have made the switch to Pitch, including top brands like Intercom, Superhuman, and Notion. Founded in 2018 by the team behind Wunderlist, and powered by a team of over 100 thinkers, makers, and storytellers, Pitch has raised over $135 million to date. To learn more and create a free account, visit pitch.com

About Lakestar

Lakestar is one of Europe's leading venture capital firms investing in technology companies led by exceptional entrepreneurs. The team’s early investments included Skype, Spotify, Facebook and airbnb. Since raising a first fund in 2013, Lakestar manages an aggregated volume of over EUR 1bn across three early stage funds, and more recently a growth fund. The company has expanded and broadened its portfolio and holds investments in the likes of Opendoor, Oscar, GYG, Glovo, Sennder, Eigen, FiveAI, Revolut and Hometogo to name a few. Lakestar has presence in Berlin, Zurich and London. Lakestar helps companies to identify new markets and expand into them rapidly, with a focus on the US and Europe. The team advises and supports portfolio companies in business development, recruitment, technology and marketing. The investments range from early stage companies to those in their growth stage. Visit us on LinkedIn and our website.

About Tiger Global Management

Tiger Global Management is a leading global technology investment firm with over $60 billion under management. The firm focuses on private and public companies in the internet, software, and financial technology sectors. Since 2001, Tiger Global has invested in hundreds of companies across more than 30 countries, including investments ranging from Series A to pre-IPO. The firm aims to partner with dynamic entrepreneurs operating market-leading companies in its core focus areas. Tiger Global’s investments have included JD.com, UiPath, Stripe, Databricks, Bytedance, Snowflake, Facebook, Alibaba, Procore, Chime, Blend, Peloton, Attentive, LinkedIn, Flipkart, and Toast.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye